江湖电竞直播ios下载

Over the weekend, SIGA said it may lose a government contract worth up to $2.8 billion for its smallpox medication because the Small Business Administration has determined it was not eligible. The smallpox contract was to be awarded to a small business under the original proposed contract by the Department of Health and Human Services.

SIGA said it plans to appeal the SBA ruling.

On Oct. 13, SIGA shared soared more than 40% on news that the company had been tentatively awarded the contract.

XenoPort Inc. XNPT   shares rose 7% to $8.59 after the company announced it had amended its collaboration agreement with GlaxoSmithKline PLC GSK, +1.21%   for the drug Horizant.

In February, XenoPort shares were crushed when U.S. regulators declined to approve the product for restless-legs syndrome, citing safety concerns.

Santarus Inc. SNTS, -0.61%   shares advanced 2% after the biotech group announced favorable Phase III clinical data for its compound budesonide MMX in the treatment of ulcerative colitis.

Athersys Inc. ATHX, -3.17%   shares also jumped 6% on ulcerative colitis news. Athersys said U.S. regulators have give the green light for the company to proceed with a Phase II clinical trial testing its stem cell therapy Multistem on patients with the debilitating disease.

Athersys is co-developing the product with Pfizer Inc. PFE, +1.61%  

The NYSE Arca Pharmaceutical Index DRG,   and the NYSE Arca Biotechnology Index BTK, +1.09%   were both marginally lower at 309.94 and 1,168.74, respectively.